Cooperative Agreement UG3DA062906
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$352K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Belmont, MA 02478, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,088,999 Project Grant to The Trustees of Columbia University in the City of New York, effective August 15, 2024 through May 31, 2029. The objective of this project is to develop efficient statistical estimators for analyzing data fusion of multi-study, multi-outcome clinical trials for treating opioid use disorder. The project aims to: 1) create parametric and...
This Cooperative Agreement award of $818,486 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the development and validation of the Stimulant Use Disorder Severity Scale (STUDSS) as a qualified Clinical Outcome Assessment (COA) and Drug Development Tool (DDT) with the U.S. Food and Drug Administration (FDA). The project, conducted by Yale University, involves three sequential stages: 1) submitting a Letter of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
This federal Cooperative Agreement award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and validate a Clinical Outcomes Assessment (COA) for opioid withdrawal management. The $702,974 award, effective June 15, 2025 through May 31, 2027, will support the Research Foundation of the City University of New York (RFCUNY) in an iterative process to expand upon existing withdrawal scales, integrate insights...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $304,215 to Carina Medical LLC to develop and validate a novel software platform for decentralized clinical trials (DCTs) in substance use disorder (SUD). The project aims to leverage large language models (LLMs) to automate data collection and improve efficiency and accuracy for SUD DCTs. Key objectives include developing the software...
This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The study aims to: 1) characterize real-world trajectories of OUD treatment in the year following hospital encounters among treatment-naive individuals and...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $208,575 to The McLean Hospital Corporation to expand mentorship of early-career investigators in patient-oriented research on substance use disorders. The award will enable the principal investigator, Dr. R. Kathryn McHugh, to dedicate more time to mentoring current and new mentees, as well as expand her own program of patient-oriented research. Key...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $155,140 to Rutgers, The State University of New Jersey to explore the relationships between substance use disorders (SUDs) and other forms of psychopathology. The research aims to use advanced quantitative and genetic methods to model the phenotypic overlap between SUDs and other psychiatric conditions, identify relevant genetic variants, and...